Latest news

  • 18 October 2018

    Sensorion Reports Pipeline Update and First-Half-Year 2018 Results. Re-design of SENS-111 Study. Read Sensorion Reports Pipeline Update and First-Half-Year 2018 Results Re-design of SENS-111 Study

  • 26 September 2018

    Sensorion Announces Publication of Seliforant Phase 1 Study Data in the British Journal of Clinical Pharmacology. Read

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more